SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 244.5 INR | -4.99% |
|
-22.61% | -14.75% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 94,683 | 50,073 | 25,274 | 37,250 | 80,734 | 58,203 |
| Enterprise Value (EV) 1 | 93,628 | 47,980 | 25,869 | 39,457 | 81,398 | 54,335 |
| P/E ratio | -47.5 x | -33.6 x | -8.09 x | -24.6 x | -38.4 x | -22.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 121 x | 27.4 x | 32.9 x | 14.7 x | 58.8 x | 24.4 x |
| EV / Revenue | 120 x | 26.2 x | 33.7 x | 15.6 x | 59.3 x | 22.8 x |
| EV / EBITDA | -38.6 x | -33.2 x | -8.42 x | -28.9 x | -43.4 x | -25.3 x |
| EV / FCF | -60.3 x | -47.7 x | -14.7 x | -34.9 x | -44.4 x | -88.9 x |
| FCF Yield | -1.66% | -2.09% | -6.81% | -2.86% | -2.25% | -1.13% |
| Price to Book | 51.3 x | 16.9 x | -136 x | -22.1 x | 259 x | 11.4 x |
| Nbr of stocks (in thousands) | 250,914 | 262,025 | 262,048 | 262,048 | 271,879 | 324,522 |
| Reference price 2 | 377.4 | 191.1 | 96.45 | 142.2 | 297.0 | 179.4 |
| Announcement Date | 8/1/18 | 7/5/19 | 9/7/20 | 9/7/21 | 8/30/22 | 7/14/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 782.6 | 1,829 | 768.1 | 2,530 | 1,372 | 2,388 |
| EBITDA 1 | -2,426 | -1,446 | -3,072 | -1,366 | -1,877 | -2,149 |
| EBIT 1 | -2,508 | -1,521 | -3,150 | -1,457 | -1,961 | -2,236 |
| Operating Margin | -320.44% | -83.18% | -410.02% | -57.6% | -142.86% | -93.66% |
| Earnings before Tax (EBT) 1 | -1,970 | -1,454 | -3,124 | -1,511 | -2,034 | -2,226 |
| Net income 1 | -1,970 | -1,454 | -3,124 | -1,511 | -2,034 | -2,226 |
| Net margin | -251.73% | -79.53% | -406.7% | -59.75% | -148.19% | -93.22% |
| EPS 2 | -7.941 | -5.690 | -11.92 | -5.768 | -7.729 | -7.818 |
| Free Cash Flow 1 | -1,553 | -1,005 | -1,761 | -1,130 | -1,833 | -611.5 |
| FCF margin | -198.41% | -54.95% | -229.23% | -44.69% | -133.56% | -25.61% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/1/18 | 7/5/19 | 9/7/20 | 9/7/21 | 8/30/22 | 7/14/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 595 | 2,207 | 663 | - |
| Net Cash position 1 | 1,055 | 2,093 | - | - | - | 3,868 |
| Leverage (Debt/EBITDA) | - | - | -0.1937 x | -1.615 x | -0.3533 x | - |
| Free Cash Flow 1 | -1,553 | -1,005 | -1,761 | -1,130 | -1,833 | -612 |
| ROE (net income / shareholders' equity) | -115% | -60.5% | -225% | 162% | 297% | -81.8% |
| ROA (Net income/ Total Assets) | -53.9% | -26.9% | -58.7% | -36.3% | -48.1% | -25.2% |
| Assets 1 | 3,654 | 5,410 | 5,325 | 4,168 | 4,230 | 8,840 |
| Book Value Per Share 2 | 7.360 | 11.30 | -0.7100 | -6.420 | 1.150 | 15.80 |
| Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0100 | 0.3600 | 0.0500 | 0.0200 |
| Capex 1 | 326 | 130 | 540 | 60 | 327 | 154 |
| Capex / Sales | 41.7% | 7.08% | 70.35% | 2.37% | 23.81% | 6.44% |
| Announcement Date | 8/1/18 | 7/5/19 | 9/7/20 | 9/7/21 | 8/30/22 | 7/14/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.75% | 1B | |
| +25.83% | 661B | |
| +26.80% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.13% | 231B | |
| +4.84% | 200B | |
| -9.37% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- SPARC Stock
- Financials Sun Pharma Advanced Research Company Limited
